|
[1]FLEMING KM, AITHAL GP, CARD TR, et al.All-cause mortality in people with cirrhosis compared with the general population:a population-based cohort study[J].Liver Int, 2012, 32 (1) :79-84.
|
|
[2]GE PS, RUNYON BA.Treatment of patients with cirrhosis[J].N Engl J Med, 2016, 375 (8) :767-777.
|
|
[3]Chinese Society of Hepatology, Chinese Medical Association.Guidelines on the management of ascites and complications in cirrhosis[J].J Clin Hepatol, 2017, 33 (10) :1847-1863. (in Chinese) 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南[J].临床肝胆病杂志, 2017, 33 (10) :1847-1863.
|
|
[4]ARROYO V, GINES P, GERBES AL, et al.Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis.International Ascites Club[J].Hepatology, 1996, 23 (1) :164-176.
|
|
[5]European Association for the Study of the Liver.EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis[J].J Hepatol, 2010, 53 (3) :397-417.
|
|
[6]RUNYON BA, AASLD.Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012[J].Hepatology, 2013, 57 (4) :1651-1653.
|
|
[7]KALAMBOKIS G, TSIANOS EV.Refractory ascites:can it be defined only by the response to furosemide and spironolactone?[J].Liver Int, 2010, 30 (9) :1394.
|
|
[8]ZHANG X, WANG SZ, ZHENG JF, et al.Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients[J].World J Gastroenterol, 2014, 20 (32) :11400-11405.
|
|
[9]MORI T, OHSAKI Y, OBA-YABANA I, et al.Diuretic usage for protection against end-organ damage in liver cirrhosis and heart failure[J].Hepatol Res, 2017, 47 (1) :11-22.
|
|
[10]SANTOS J, PLANAS R, PARDO A, et al.Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis.A randomized comparative study of efficacy and safety[J].J Hepatol, 2003, 39 (2) :187-192.
|
|
[11]PEREZ-AYUSO RM, ARROYO V, PLANAS R, et al.Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites.Relationship between the diuretic response and the activity of the renin-aldosterone system[J].Gastroenterology, 1983, 84 (5 Pt 1) :961-968.
|
|
[12]PIANO S, TONON M, ANGELI P.Management of ascites and hepatorenal syndrome[J].Hepatol Int, 2017.[Epub ahead of print]
|
|
[13]FIMIANI B, GUARDIA DD, PUOTI C, et al.The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function:a multicentric study[J].Eur J Intern Med, 2011, 22 (6) :587-590.
|
|
[14]ACEVEDO JG, CRAMP ME.Hepatorenal syndrome:update on diagnosis and therapy[J].World J Hepatol, 2017, 9 (6) :293-299.
|
|
[15]SANYAL AJ, BOYER TD, FREDERICK RT, et al.Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs.placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies[J].Aliment Pharmacol Ther, 2017, 45 (11) :1390-1402.
|
|
[16]CAVALLIN M, PIANO S, ROMANO A, et al.Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:a randomized controlled study[J].Hepatology, 2016, 63 (3) :983-992.
|
|
[17]SINGH V, DHUNGANA SP, SINGH B, et al.Midodrine in patients with cirrhosis and refractory or recurrent ascites:a randomized pilot study[J].J Hepatol, 2012, 56 (2) :348-354.
|
|
[18]GINES P, WONG F, WATSON H, et al.Clinical trial:shortterm effects of combination of satavaptan, a selective vasopressin V2receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia——a randomized, double-blind, placebo-controlled study[J].Aliment Pharmacol Ther, 2010, 31 (8) :834-845.
|
|
[19]RAI N, SINGH B, SINGH A, et al.Midodrine and tolvaptan in patients with cirrhosis and refractory or recurrent ascites:a randomised pilot study[J].Liver Int, 2017, 37 (3) :406-414.
|
|
[20]BERNARDI M, CARACENI P, NAVICKIS RJ.Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis?[J].Expert Rev Gastroenterol Hepatol, 2017, 11 (3) :191-192.
|
|
[21]ALLESANDRIA C, ELLA C, MEZZABITTA L, et al.Prevention of paracentesis-induced circulatory dysfunction in cirrhosis:standard vs half albumin doses.A prospective, randomized, unblinded pilot study[J].Dig Liver Dis, 2011, 43 (11) :881-886.
|
|
[22]JOHNSON KB, MUELLER JL, SIMON TG, et al.Reduced albumin dosing during large-volume paracentesis is not associated with adverse clinical outcomes[J].Dig Dis Sci, 2015, 60 (7) :2190-2195.
|
|
[23]SINGH V, KUMAR R, NAIN CK, et al.Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis:a randomized study[J].J Gastroenterol Hepatol, 2006, 21 (1 Pt 2) :303-307.
|
|
[24]CAI ZH, FAN CL, ZHENG JF, et al.Measurement of serum procalcitonin levels for the early diagnosis of spontaneous bacterial peritonitis in patients with decompensated liver cirrhosis[J].BMC Infect Dis, 2015, 15:55.
|
|
[25]USAMI M, MIYOSHI M, YAMASHITA H, et al.Gut microbiota and host metabolism in liver cirrhosis[J].World J Gastroenterol, 2015, 21 (41) :11597-11608.
|
|
[26]BAJAJ JS, KASSAM Z, FAGAN A, et al.Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:a randomized clinical trial[J].Hepatology, 2017, 66 (6) :1727-1738.
|
|
[27]GRAT M, WRONKA KM, KRASNODEBSKI M, et al.Profile of gut microbiota associated with the presence of hepatocellular cancer in patients with liver cirrhosis[J].Transplant Proc, 2016, 48 (5) :1687-1691.
|
|
[28]IBRAHIM ES, ALSEBAEY A, ZAGHLA H, et al.Long-term rifaximin therapy as a primary prevention of hepatorenal syndrome[J].Eur J Gastroenterol Hepatol, 2017, 29 (11) :1247-1250.
|
DownLoad: